Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT02584504

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02584504
Other papers using this trial's data
  • Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON Journal of cardiology, 2019-03 DOI, PubMed 30509509

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02584504. Randomized; quadruple masking; primary purpose treatment. Start 2015-11-30 (actual); primary completion 2017-04-05 (actual). Results posted on 2018-05-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Acronym
ODYSSEY-NIPPON
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Non-statin Lipid-Modifying Therapy
Intervention (Other)
Diet Alone
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02584504
Content hash
5fe86e04e987e25055178f7e5cb245f5dce26314f7b82b7ec6c8b4b64a5ff5aa